Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have earned an average rating of “Moderate Buy” from the five research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $17.25.

A number of brokerages have recently commented on ENTA. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. Robert W. Baird reduced their target price on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. StockNews.com upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, JMP Securities reiterated a “market outperform” rating and set a $21.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th.

Enanta Pharmaceuticals Stock Performance

ENTA stock opened at $7.49 on Friday. Enanta Pharmaceuticals has a 52 week low of $4.71 and a 52 week high of $17.80. The company has a market capitalization of $159.76 million, a PE ratio of -1.37 and a beta of 0.54. The company’s 50-day simple moving average is $5.69 and its 200 day simple moving average is $9.31.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. On average, analysts forecast that Enanta Pharmaceuticals will post -5.05 EPS for the current year.

Insider Transactions at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the sale, the chief executive officer now owns 801,638 shares of the company’s stock, valued at approximately $6,461,202.28. This represents a 0.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 13.89% of the company’s stock.

Institutional Trading of Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ENTA. China Universal Asset Management Co. Ltd. bought a new stake in shares of Enanta Pharmaceuticals in the 4th quarter worth approximately $26,000. Tower Research Capital LLC TRC boosted its position in Enanta Pharmaceuticals by 46.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 2,274 shares in the last quarter. US Bancorp DE grew its holdings in shares of Enanta Pharmaceuticals by 4,933.7% during the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 4,243 shares during the period. Intech Investment Management LLC purchased a new position in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $58,000. Finally, Squarepoint Ops LLC bought a new position in shares of Enanta Pharmaceuticals in the 4th quarter worth approximately $66,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.